chalcone has been researched along with 2019 Novel Coronavirus Disease in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aktas, DA; Alagoz, MA; Algul, O; Anil, B; Ay, E; Burmaoglu, S; Cimen, F; Duran, N; Polat, MF; Tek, E | 1 |
| Bouachrine, M; Bouayyadi, L; El Aissouq, A; Khalil, F; Ouammou, A | 1 |
| Di Giacomo, S; Di Sotto, A; Irannejad, H; Valipour, M | 1 |
3 other study(ies) available for chalcone and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
New chalcone derivatives as effective against SARS-CoV-2 agent.
Topics: Antiviral Agents; Chalcone; Chalcones; COVID-19; Humans; SARS-CoV-2 | 2021 |
Structure-based virtual screening of novel natural products as chalcone derivatives against SARS-CoV-2 M
Topics: Biological Products; Chalcone; Chalcones; COVID-19; Humans; Molecular Docking Simulation; Molecular Dynamics Simulation; Protease Inhibitors; SARS-CoV-2 | 2023 |
Discovery of Chalcone-Based Hybrid Structures as High Affinity and Site-Specific Inhibitors against SARS-CoV-2: A Comprehensive Structural Analysis Based on Various Host-Based and Viral Targets.
Topics: Antiviral Agents; Chalcone; Chalcones; COVID-19; Cysteine Endopeptidases; Humans; Molecular Docking Simulation; Protease Inhibitors; SARS-CoV-2 | 2023 |